Keros Therapeutics, Inc. Common Stock
Market Cap
200M
Short interest (Jul 15)
5.4%
Net Short (Jul 27 ): -0.1%
Borrow Fee
0.66%
↓ 30.5%
Available Shares
600K
↓ 34.8%
Price Chart
Company Overview
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
Company Info
Market Data
Short Interest
Recent Changes
Quick Actions
Investment Risk
This is not financial advice. All investments carry risk. Do your own research before making investment decisions.